Dohj LLC Makes New $259,000 Investment in Eli Lilly and Company (NYSE:LLY)

Dohj LLC bought a new position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 314 shares of the company's stock, valued at approximately $259,000.

A number of other hedge funds have also added to or reduced their stakes in the business. Knightsbridge Asset Management LLC increased its holdings in shares of Eli Lilly and Company by 1.9% during the fourth quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company's stock valued at $628,000 after acquiring an additional 15 shares in the last quarter. Centerpoint Advisory Group acquired a new position in Eli Lilly and Company during the fourth quarter worth $514,000. LS Investment Advisors LLC lifted its stake in shares of Eli Lilly and Company by 1.7% in the first quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock valued at $1,933,000 after buying an additional 40 shares in the last quarter. CSM Advisors LLC lifted its stake in shares of Eli Lilly and Company by 30.6% in the fourth quarter. CSM Advisors LLC now owns 1,045 shares of the company's stock valued at $807,000 after buying an additional 245 shares in the last quarter. Finally, Proficio Capital Partners LLC grew its holdings in shares of Eli Lilly and Company by 30.2% during the fourth quarter. Proficio Capital Partners LLC now owns 6,739 shares of the company's stock valued at $5,202,000 after buying an additional 1,562 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock traded down $15.97 on Tuesday, reaching $791.61. 2,873,403 shares of the company traded hands, compared to its average volume of 3,651,853. The company has a 50 day moving average of $777.10 and a 200 day moving average of $801.77. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53. The firm has a market capitalization of $750.24 billion, a PE ratio of 58.69, a PEG ratio of 1.18 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. During the same quarter in the previous year, the company posted $2.58 EPS. Eli Lilly and Company's revenue for the quarter was up 45.2% on a year-over-year basis. Equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Friday, May 16th were issued a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.76%. The ex-dividend date of this dividend was Friday, May 16th. Eli Lilly and Company's dividend payout ratio (DPR) is currently 48.82%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Erste Group Bank lowered shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Wells Fargo & Company reissued an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Guggenheim restated a "buy" rating on shares of Eli Lilly and Company in a report on Friday, May 23rd. UBS Group decreased their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Finally, HSBC lowered Eli Lilly and Company from a "buy" rating to a "reduce" rating and lowered their price target for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. One analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company currently has an average rating of "Moderate Buy" and a consensus price target of $1,011.37.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.